BioCrea GmbH

Radebeul, Germany

BioCrea GmbH

Radebeul, Germany

Time filter

Source Type

News Article | December 16, 2016
Site: marketersmedia.com

— Huntington Disease - Companies Involved in Therapeutics Development are Addex Therapeutics Ltd, AFFiRiS AG, Angita BV, Annexon Inc, Astellas Pharma Inc, Azevan Pharmaceuticals Inc, BioCrea GmbH, BrainStorm Cell Therapeutics Inc, Celon Pharma Sp z oo, Chong Kun Dang Pharmaceutical Corp, Diffusion Pharmaceuticals Inc, EncephRx Inc, Evotec AG, Galenea Corp, Genervon Biopharmaceuticals LLC, Horizon Pharma Plc, Immungenetics AG, Ionis Pharmaceuticals Inc, Ipsen SA, Kadmon Corp LLC, KineMed Inc, Krenitsky Pharmaceuticals Inc, Living Cell Technologies Ltd, Medesis Pharma SA, Mitochon Pharmaceuticals Inc, Neuralstem Inc, Neurimmune Holding AG, NeuroNascent Inc, New World Laboratories Inc, nLife Therapeutics SL, NsGene A/S, Omeros Corp, Oryzon Genomics SA, Pfizer Inc, PharmatrophiX Inc, ProQR Therapeutics NV, QR Pharma Inc, reMYND NV, Retrotope Inc, Rhenovia Pharma Ltd, Shire Plc, SOM Biotech SL, Spark Therapeutics Inc, Teva Pharmaceutical Industries Ltd, TyrNovo Ltd, Ultragenyx Pharmaceutical Inc, UniQure NV, Vaccinex Inc, Vertex Pharmaceuticals Inc, VistaGen Therapeutics Inc, Vitality Biopharma Inc, VivaCell Biotechnology Espana SL, Voyager Therapeutics Inc, Vybion Inc, WAVE Life Sciences Ltd and Wellstat Therapeutics Corp. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10, 5, 46 and 17 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 19 and 4 molecules, respectively. Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Inquire more about this report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786898 Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/786898-huntington-disease-pipeline-review-h2-2016.html


— Amyotrophic Lateral Sclerosis Pipeline Market Companies Involved in Therapeutics Development are 2-BBB Medicines BV, AB Science SA, Aestus Therapeutics Inc, Anavex Life Sciences Corp, Angion Biomedica Corp, Apodemus AB, Apogenix GmbH, Apotex Inc, ArmaGen Inc, BioCrea GmbH, Biogen Inc, Biohaven Pharmaceutical Holding Company Limited, BioHealthonomics Inc, BrainStorm Cell Therapeutics Inc, Calico LLC, Catabasis Pharmaceuticals Inc, Cellceutix Corp, Chronos Therapeutics Ltd, ContraVir Pharmaceuticals Inc, Corcept Therapeutics Inc, Curatis Pharma GmbH, Cytokinetics Inc, Daval International Ltd, Edison Pharmaceuticals Inc, Eisai Co Ltd, Ensemble Therapeutics Corp, Evotec AG, F. Hoffmann-La Roche Ltd, Flex Pharma, Inc., FPRT Bio Inc, Gemac, Genentech Inc, Genervon Biopharmaceuticals LLC, GeNeuro SA, GenKyoTex SA, Glialogix Inc, Grifols SA, Herantis Pharma Plc, ImStar Therapeutics Inc., InFlectis BioScience, Ionis Pharmaceuticals Inc, Italfarmaco SpA, Jeil Pharmaceutical Co Ltd, Kadimastem Ltd, Karyopharm Therapeutics Inc, KineMed Inc, Kringle Pharma Inc, Kyorin Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Lascco SA, Lead Discovery Center GmbH, M's Science Corp, Maas Biolab, Mallinckrodt Plc, MedDay SA, MeiraGTx Limited, miCure Therapeutics Ltd., miRagen Therapeutics Inc, MitoDys Therapeutics Limited, Mitsubishi Tanabe Pharma Corp, Neuralstem Inc, Neuraltus Pharmaceuticals Inc, Neurimmune Holding AG, Neurotec Pharma SL, Neurotune AG, Orion Oyj, Orphazyme ApS, Pharnext SA, Plex Pharmaceuticals Inc, Prevacus Inc, Primary Peptides, Inc., ProMIS Neurosciences Inc, Q Therapeutics Inc, ReceptoPharm Inc, Regenesance BV, reMYND NV, Saneron CCEL Therapeutics Inc, SciFluor Life Sciences LLC, SK Biopharmaceuticals Co Ltd, Spherium Biomed SL, Symic Biomedical Inc, Teva Pharmaceutical Industries Ltd, Thera Neuropharma Inc, Treeway BV, Valeant Pharmaceuticals International Inc, ViroMed Co Ltd, VivaCell Biotechnology Espana SL, Voyager Therapeutics Inc, WAVE Life Sciences Ltd and Yooyoung Pharmaceutical Co Ltd. This research provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774107 The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 2, 23, 12, 2, 74, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 9 molecules, respectively. Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774107 • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774107-amyotrophic-lateral-sclerosis-pipeline-review-h2-2016.html


News Article | November 16, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Schizophrenia - Pipeline Review, H2 2016 addition with 118 market data tables and 17 figures, spread across 349 pages is available at http://www.reportsnreports.com/reports/747736-schizophrenia-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Alkermes Plc ,Angita B.V. ,Astellas Pharma Inc. ,Athersys, Inc. ,Avanir Pharmaceuticals, Inc.,Avineuro Pharmaceuticals, Inc.,BCWorld Pharm Co. Ltd.,BioCrea GmbH BioHealthonomics Inc ,Boehringer Ingelheim GmbH,Braeburn Pharmaceuticals, Inc.,Bristol-Myers Squibb Company,Critical Pharmaceuticals Limited,Curemark, LLC ,Delpor, Inc. ,Denovo Biopharma, LLC,Echo Pharmaceuticals,B.V.,Egis Gyogyszergyar Nyrt,Evotec AG ,F. Hoffmann-La Roche Ltd.,Fabre-Kramer Pharmaceuticals, Inc. Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=747736this is a premium report price at US$2000 for a single user PDF license).


Krotzky T.,University of Marburg | Grunwald C.,BioCrea GmbH | Egerland U.,BioCrea GmbH | Klebe G.,University of Marburg
Journal of Chemical Information and Modeling | Year: 2015

Determination of structural similarities between protein binding pockets is an important challenge in in silico drug design. It can help to understand selectivity considerations, predict unexpected ligand cross-reactivity, and support the putative annotation of function to orphan proteins. To this end, Cavbase was developed as a tool for the automated detection, storage, and classification of putative protein binding sites. In this context, binding sites are characterized as sets of pseudocenters, which denote surface-exposed physicochemical properties, and can be used to enable mutual binding site comparisons. However, these comparisons tend to be computationally very demanding and often lead to very slow computations of the similarity measures. In this study, we propose RAPMAD (RApid Pocket MAtching using Distances), a new evaluation formalism for Cavbase entries that allows for ultrafast similarity comparisons. Protein binding sites are represented by sets of distance histograms that are both generated and compared with linear complexity. Attaining a speed of more than 20 000 comparisons per second, screenings across large data sets and even entire databases become easily feasible. We demonstrate the discriminative power and the short runtime by performing several classification and retrieval experiments. RAPMAD attains better success rates than the comparison formalism originally implemented into Cavbase or several alternative approaches developed in recent time, while requiring only a fraction of their runtime. The pratical use of our method is finally proven by a successful prospective virtual screening study that aims for the identification of novel inhibitors of the NMDA receptor. © 2014 American Chemical Society.


Hoefgen N.,Biocrea GmbH | Grunwald C.,Biocrea GmbH | Langen B.,Biocrea GmbH
Drugs of the Future | Year: 2012

Current treatments for schizophrenia, such as dopamine D2 receptor antagonists and second-generation antipsychotics, are effective at alleviating positive symptoms but have limited impact on negative symptoms and cognitive deficits. In parallel, the extrapyramidal symptoms, hyperprolactinemia and metabolic syndrome, including substantial weight gain, are typical side effects limiting the value of many of these drugs for patients. Due to its expression pattern and functionality in brain areas associated with this disease, phosphodiesterase 10A (PDE10A) appears to be a promising novel target for the treatment of schizophrenia and the base for the development of drugs with an alternative therapeutic approach. Structurally diverse sets of inhibitors have been discovered with the extensive use of structure-based technologies. Two different binding modes of inhibitors in the catalytic domain for, respectively, glutamine and/or tyrosine of the enzyme have been detected which were used for the rational design of development candidates. Selected lead compounds were broadly characterized in animal models of schizophrenia. The efficacy of PDE10A inhibitors in models of positive, negative or cognitive symptoms and the in vivo profile that hints at a reduced side effect potential indicate that these programs could deliver promising novel treatments for schizophrenic patients. First trials for clinical validation are under way. Copyright © 2012 Prous Science, S.A.U. or its licensors. All rights reserved.


Gewald R.,Biocrea GmbH | Rueger C.,Biocrea GmbH | Grunwald C.,Biocrea GmbH | Egerland U.,Biocrea GmbH | Hoefgen N.,Biocrea GmbH
Bioorganic and Medicinal Chemistry Letters | Year: 2011

The synthesis and SAR studies of a series of structurally novel inhibitors of PDE7 are discussed. The best compounds from the series display low nanomolar inhibitory activity and are selective versus other PDE isoenzymes. © 2011 Elsevier Ltd. All rights reserved.


Gewald R.,BioCrea GmbH | Grunwald C.,BioCrea GmbH | Egerland U.,BioCrea GmbH
Bioorganic and Medicinal Chemistry Letters | Year: 2013

Expanding on HTS hit 4 afforded a series of [1,3,5]triazine derivatives as novel PDE4 inhibitors. The SAR development and optimization process with the emphasis on ligand efficiency and physicochemical properties led to the discovery of compound 44 as a potent, selective and orally active PDE4 inhibitor. © 2013 Elsevier Ltd. All rights reserved.


Langen B.,biocrea GmbH | Dost R.,biocrea GmbH
ADHD Attention Deficit and Hyperactivity Disorders | Year: 2011

Spontaneously hypertensive rats (SHR) and its counterpart, the Wistar-Kyoto rats (WKY), are probably the most often used animal model of ADHD. However, SHR as model of ADHD have also been criticised partly because of not differing to outbred rat strains. In the present study, adolescent SHR, WKY and Wistar rats from Charles River were tested in open-field, elevated plus maze and novel object recognition and on gastrointestinal transport to more intensively evaluate the strain characteristics. Non-habituated SHR and Wistar rats were more active than WKY rats but contrary to Wistar rats SHR stay hyperactive in a familiar environment. SHR were more sensitive to the alpha2-adrenoceptor agonist guanfacine and the dopamine D1 agonist A-68930 than WKY and Wistar rats, whereas amphetamine, the D1/D5 agonist ABT431 and the D2 agonist quinpirole, similarly affected open-field activity in all strains. In the elevated plus maze, SHR and Wistar rats showed less anxiety-related behaviour than WKY rats. Guanfacine and amphetamine induced an anxiolytic-like activity in SHR but not in WKY and Wistar rats. SHR showed the highest long-term memory in the novel object recognition. Gastrointestinal transport was similar and comparably affected by guanfacine in all rat strains. The present study shows clear differences in the behaviour of SHR and Wistar rats but also of WKY and Wistar rats. The use of SHR as animal model of ADHD is supported. © 2010 Springer-Verlag.


PubMed | Helmholtz Center Dresden and BioCrea GmbH
Type: Journal Article | Journal: Journal of labelled compounds & radiopharmaceuticals | Year: 2016

Cyclic nucleotide phosphodiesterase 10A (PDE10A) regulates the level of the second messengers cAMP and cGMP in particular in brain regions assumed to be associated with neurodegenerative and psychiatric diseases. A better understanding of the pathophysiological role of the expression of PDE10A could be obtained by quantitative imaging of the enzyme by positron emission tomography (PET). Thus, in this study we developed, radiolabeled, and evaluated a new PDE10A radioligand, 8-bromo-1-(6-[


PubMed | Helmholtz Center Dresden and BioCrea GmbH
Type: | Journal: European journal of medicinal chemistry | Year: 2015

Herein we report the synthesis of fluorinated inhibitors of phosphodiesterase 10A (PDE10A) which can be used potentially as lead structure for the development of a (18)F-labeled PDE10A imaging agent for positron emission tomography. The use of ortho-fluoropyridines as residues could potentially enable the introduction of (18)F through nucleophilic substitution for radiolabeling purposes. 2-Fluoropyridines are introduced by a Suzuki coupling at different positions of the molecule. The reference compounds, 1,8-dipyridinylimidazo[1,5-a]quinoxalines and 1-pyridinylimidazo[1,5-a]quinoxalines, show inhibitory potencies at best in the subnanomolar range and selectivity factors greater than 38 against other PDEs. 1,8-Dipyridinylimidazo[1,5-a]quinoxalines are more potent inhibitors than 1-pyridinylimidazo[1,5-a]quinoxalines. Using 2-fluoro-3-pyridinyl as residue provided the most potent inhibitors 16 (IC50 = 0.12 nM), 17 (IC50 = 0.048 nM) and 32 (IC50 = 0.037 nM).

Loading BioCrea GmbH collaborators
Loading BioCrea GmbH collaborators